国信证券晨会纪要-20250724

Industry and Company Insights - The pharmaceutical sector outperformed the overall market, with a 4.00% increase in the biopharmaceutical sector, driven by a 6.86% rise in the chemical pharmaceutical segment [8][9] - China National Pharmaceutical plans to acquire Lixin Pharmaceutical for a valuation of $1 billion, enhancing its technological platform and international capabilities [9][10] - The electric power equipment and new energy sector is optimistic about the establishment of China Fusion Energy Co., which has attracted investments totaling 11.5 billion yuan [11] - The food and beverage sector saw a decrease in fund holdings in the liquor segment, while the consumer goods segment experienced slight increases [12][14] - The automotive industry reported a 13.8% year-on-year increase in sales, with new energy vehicles accounting for 45.8% of total new car sales in June 2025 [15][16] Financial Engineering - The public FOF fund market saw a 10.01% increase in total scale, reaching 166.198 billion yuan by Q2 2025, with a median return of 2.62% for equity-focused FOFs [24][25] - The number of FOF products reached 518, with a significant portion allocated to equity and balanced funds [24][25] Company-Specific Analysis - Keda Li (002850.SZ) reported a net profit of 750-820 million yuan for H1 2025, reflecting a year-on-year increase of 16%-27% [22] - TBEA (600089.SH) is expected to benefit from the coal industry's recovery due to a recent government initiative to stabilize coal supply and pricing [23]